Status:
UNKNOWN
COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
The First Affiliated Hospital of Shanxi Medical University
Shandong Provincial Hospital
Conditions:
Amnestic Mild Cognitive Impairment
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
This study evaluates the efficacy and mechanism of internet-based cognitive training in patients with amnestic mild cognitive impairment (aMCI). Half of participants will receive multi-domain adaptive...
Detailed Description
Background: Alzheimer's disease (AD) is the most common dementia and the major cause for senile dementia. With the increase of life expectancy, AD has become a global problem. However, to date, drug t...
Eligibility Criteria
Inclusion
- Literate Han Chinese, 50-85 years of age with a caregiver that accompanies the subject consistently at least 4 days a week;
- Complaint and/or informant report of a cognitive impairment lasting for at least 3 months;
- Clinical diagnosis of MCI according to the MCI core clinical criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines;
- A prominent manifestation of memory deficit with or without other cognitive domain impairments;
- Mini-Mental State Examination (MMSE) score ≥24, and Clinical dementia rating (CDR) = 0.5, and
- Normal or slightly impaired activities of daily living as defined by a total score of ≤ 1.5 on the three functional CDR domains (home and hobbies, community affairs, and personal care).
Exclusion
- Severe aphasia, physical disabilities, or any other disease that may preclude completion of neuropsychological testing;
- A medical history of stroke with focal neurological features including hemiparesis, sensory loss, visual field deficits, and evidence of responsible lesions on MRI;
- Significant white matter lesions (Fazekas score = 3-6);
- Disorders other than aMCI that may affect cognition;
- Depression or other psychiatric disorders;
- Clinically significant gastrointestinal, renal, hepatic, respiratory, infectious, endocrine, or cardiovascular diseases, cancer, alcoholism, drug addiction;
- Use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents;
- Inability to undergo a brain MRI; and
- Other conditions that in the investigator's opinion might not be suitable for the study.
Key Trial Info
Start Date :
November 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04063956
Start Date
November 6 2019
End Date
December 1 2023
Last Update
July 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, China, 100053